Keywords: ایرینوتکان; Irinotecan; Oxaliplatin; 5-fluorouracil; Antiepidermal growth factor receptor antibody; Vascular endothelial growth factor antibody; Immunotherapy; Regorafenib; Trifluridine/tipiracil;
مقالات ISI ایرینوتکان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایرینوتکان; Irinotecan; Diet; NAFLD; Diarrhea; Steatosis; SN-38; Lard;
Keywords: ایرینوتکان; Chemotherapy; evidence-based clinical practice guideline; irinotecan; platinum-etoposide; radiation; small cell lung cancer;
Keywords: ایرینوتکان; Breast cancer; Celastrol; Folic acid; Irinotecan; Liposomes;
Keywords: ایرینوتکان; Peptides; Drug monitoring; In silico design; Irinotecan;
Keywords: ایرینوتکان; Irinotecan; Metabolites; Therapeutic drug monitoring; Voltammetry; Acetonitrile;
Keywords: ایرینوتکان; ÎΨ; Mitochondrial Membrane Potential; 5FU; 5-Flurouracil; ANOVA; Analysis of Variance; ANT; Adenine Nucleotide Transporter; CAs; Chemotherapeutic Agents; CI-V; Complex I-V; Cu2 +;  Copper; DM; Differentiation Media; DMEM; Dulbecco's Modified Eagle's
Keywords: ایرینوتکان; Human serum albumin; Nanoparticles; Irinotecan; Polysorbate 80; Tween 80; High pressure homogenisation; Factorial design; Stability studies;
Keywords: ایرینوتکان; Pancreatic cancer; Second line; Chemotherapy; Oxaliplatin; Irinotecan; Review;
Keywords: ایرینوتکان; Irinotecan; Steatohepatitis; Silymarin; Cancer chemotherapy toxicity; Inflammation; Liver;
Keywords: ایرینوتکان; Polypeptides; Amphiphilic block-copolymers; Nanoparticles; Encapsulation; Irinotecan; Cellular uptake; Biodegradation;
Keywords: ایرینوتکان; Magnetic nanoparticles; Magnetic graphene oxide; Doxorubicin; Irinotecan; Drug delivery;
Keywords: ایرینوتکان; Cancer; Citrate; Cyclodextrin; Irinotecan; Magnetic nanoparticle;
Keywords: ایرینوتکان; EPT; enzyme prodrug therapy; NSC; neural stem cells; MSC; mesenchymal stromal cells; NK; natural killer cells; iPSCs; induced pluripotent stem cells; HSV-TK; herpes simplex virus thymidine kinase; GCV; ganciclovir; 5-FC; 5-Flurocytosine; 5-FU; 5-Flurouric
Keywords: ایرینوتکان; Biomarker; Ceramide; Stereotactic radiotherapy; Irinotecan; Metastases;
Keywords: ایرینوتکان; Metastatic breast cancer; Metastatic colorectal cancer; Trastuzumab; Bevacizumab; Anthracycline; Cyclophosphamide; Paclitaxel; Irinotecan; Fluorouracil; Leucovorin;
Keywords: ایرینوتکان; Cervical cancer; Neoadjuvant chemotherapy; Irinotecan; Paclitaxel; Cisplatin;
Keywords: ایرینوتکان; Oxaliplatin; Irinotecan; Co-loaded liposomes; Synchronous release; Co-delivery; Combination therapy;
Keywords: ایرینوتکان; Cetuximab; fluorouracil; irinotecan; oxaliplatin; radiosensitisation;
Keywords: ایرینوتکان; Cytostatic agents; Emerging contaminants; Environmental samples; Liquid chromatography; Gas chromatography; 5-FU; 5-Fluorouracil; ACT-D; actinomycin-D; A-GLU; Aminoglutethimide; APCI; atmospheric pressure chemical ionization; APPI; atmospheric pressure ph
Keywords: ایرینوتکان; Carboxylesterases; Immunological liver injury; Imidapril; Irinotecan;
Keywords: ایرینوتکان; Irinotecan; Excitation-emission-kinetic fluorescence; Second-order calibration; Alternating normalization-weighted error algorithm; Lactone hydrolysis kinetics;
Keywords: ایرینوتکان; Irinotecan; Magnetic nanoparticles; Protein; Fluorescence spectroscopy; Horowitz-Metzger method;
Keywords: ایرینوتکان; CRAd; Oncolytic adenoviruses; Chemotherapeutic; 5-FU; 5-fluorouracil; Î24; 24 nucleotide deletion in CR2 domain of E1A region; Ad; adenovirus; AFP; α-foetoprotein; ATC; anaplastic thyroid cancer; CPA; cyclophosphamide; CPT-11; irinotecan; CR2; conserved
Keywords: ایرینوتکان; Drug resistance; Re-challenge; Overcome resistance; Oxaliplatin; Irinotecan; Bevacizumab; 5-Fluorouracil; Cetuximab
Keywords: ایرینوتکان; Metastatic colorectal cancer; Irinotecan; Oxaliplatin; Cetuximab; Bevacizumab; Chemotherapy regimen sequencing; FOLFIRI; FOLFOX
Keywords: ایرینوتکان; Irinotecan; Probiotics; Diarrhea; Prevention
A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis
Keywords: ایرینوتکان; Phase II clinical trial; Endometrial cancer; Irinotecan; Chemotherapy;
Food-drug interactions involving multiple mechanisms: A case study with effect of Capsaicin on the pharmacokinetics of Irinotecan and its main metabolites in rat
Keywords: ایرینوتکان; APC; 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxy-camptothecin; AUC; Area under the plasma concentration-time curve; CAP; Capsaicin; CES; Carboxylesterase; CPT; Camptothecin; CPT-11; Irinotecan; CYP; cytochrome P450; DMEs; Drug-meta
Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer
Keywords: ایرینوتکان; Chemoradiotherapy; Irinotecan; Rectal cancer; Tegafur; Uracil;
Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1
Keywords: ایرینوتکان; Prostate cancer; Simvastatin; Irinotecan; Apoptosis;
Plasma citrulline is a sensitive safety biomarker for small intestinal injury in rats
Keywords: ایرینوتکان; P5CS; pyrroline-5-carboxylate synthase; ASS; argininosuccinate synthase; ASL; argininosuccinate lyase; AST; aspartate aminotransferase; ALT; alanine aminotransferase; GLS; glutaminase; OAT; ornithine aminotransferase; OCT; ornithine carbamoyltransferase;
Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells
Keywords: ایرینوتکان; CRCColorectal cancer; ITIrinotecan; OPTOxaliplatin; EMTEpithelial-mesenchymal transition; ABCATP binding cassette; MRPMultidrug resistance-associated protein; Primary cell lines; Metastatic colon cancer; Oxaliplatin; Irinotecan; Drug resistance; Epithelia
Darunavir alleviates irinotecan-induced intestinal toxicity in Vivo
Keywords: ایرینوتکان; Darunavir; Irinotecan; Inflammation; HMGB1; NLRP3;
Practical fluorimetric assay for the detection of anticancer drug SN-38 in human plasma
Keywords: ایرینوتکان; Irinotecan; SN-38; Therapeutic drug monitoring; Fluorescence; Anticancer drugs; Diagnostics; Oncology;
Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection
Keywords: ایرینوتکان; Irinotecan; SN-38; Dried blood spots; High-performance liquid chromatography; Fluorescence detection; Therapeutic drug monitoring;
Effects of Î9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats
Keywords: ایرینوتکان; CPT-11; Irinotecan; THC; Rat; Urine;
Role of regulatory T cells in irinotecan-induced intestinal mucositis
Keywords: ایرینوتکان; IM; intestinal mucositis; Treg; regulatory T cells; Th; T helper cell; DAMPs; damage-associated molecular patterns; TLR; Toll Like Receptors; DSS; dextran sodium sulfate; MPO; myeloperoxidase; FOXP3; Forkhead box P3; ROR; related orphan receptor; Intestin
E4bp4 regulates carboxylesterase 2 enzymes through repression of the nuclear receptor Rev-erbα in mice
Keywords: ایرینوتکان; bZip; the basic leucine zipper; CAR; constitutive androstane receptor; Ces/CES; mouse and human carboxylesterases; ChIP; chromatin immunoprecipitation assay; Co-IP; co-immunoprecipitation; CYP7A1; cholesterol 7alpha-hydroxylase; DMEM; Dulbecco's modifie
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901
Keywords: ایرینوتکان; Amrubicin; Irinotecan; Carboplatin; Chemotherapy; Phase II study; Small-cell lung cancer;
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Keywords: ایرینوتکان; Clinical trial; Phase II; Ovarian cancer; Bevacizumab; Irinotecan;
Solid dispersions of drugs in hyaluronan matrix: The role of the biopolymer in modulating drug activity in vivo
Keywords: ایرینوتکان; Hyaluronic acid; Solid dispersion; Raloxifene; Letrozole; Irinotecan; Pharmacokinetics;
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
Keywords: ایرینوتکان; UGT1A1 enzyme; Diarrhea; Irinotecan; Shengjiangxiexin decoction;
Electrochemistry of conjugated planar anticancer molecules: Irinotecan and Sunitinib
Keywords: ایرینوتکان; Anticancer molecule; Electrochemistry; Irinotecan; Sunitinib; Electronic spectra;
Original ArticleSynergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer
Keywords: ایرینوتکان; Sunitinib; Irinotecan; Anaplastic thyroid cancer; Synergism; Tumor xenografts;
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells
Keywords: ایرینوتکان; Equilibrative nucleoside transporter 1; Uridine; Decitabine; Deoxycytidine kinase; Monophosphorylation; Irinotecan; Etoposide; Cytarabine; Gemcitabine; Kinetics;
Irinotecan-induced bile acid malabsorption is associated with down-regulation of ileal Asbt (Slc10a2) in mice
Keywords: ایرینوتکان; CPT-11; irinotecan; TBAs; total bile acids; BAM; bile acid malabsorption; ASBT; apical Na+-dependent bile salt transporter; EHC; enterohepatic circulation; IS; internal standard; NDCA; nor-desoxycholic acid; d4-CDCA; d4-chenodeoxycholic; CA; cholic acid;
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification
Keywords: ایرینوتکان; Irinotecan; Dose intensification; 5-Fluorouracil dose adaptation; Dihydropyrimidine deshydrogenase; DPD;
Full length articleIrinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration
Keywords: ایرینوتکان; Irinotecan; Double-reversible thermogel; Burst effect; Toxicity; Anti-tumour efficacy;
Clinical TrialGeriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients
Keywords: ایرینوتکان; Colorectal cancer; Elderly; Geriatric assessment; Prognostic factors; Irinotecan;